Status:
WITHDRAWN
Effects on Atherosclerosis Regression of Ezetimibe or Ezetimibe Plus Simvastatin; Evaluated by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
Lead Sponsor:
Korea University
Conditions:
Atherosclerosis
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising tool for identifying and quantifying vascular inflammation within atherosclerotic plaques. Therefore, in this study the i...
Eligibility Criteria
Inclusion
- hsCRP \> 2 mg/L and LDL cholesterol \> 130 mm/dL
Exclusion
- history of cardiovascular disease
- diabetes
- uncontrolled hypertension
- active infection
- previous anti-hyperlipidemic agents within 6 months
- previous steroid or anti-inflammatory agents within 6 months
- liver disease
- renal disease
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00926055
Start Date
September 1 2011
Last Update
March 18 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Korea University Guro
Seoul, South Korea, 152-050